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A B S T R A C T
Purpose
To determine treatment and aging-related effects on longitudinal cognitive function in older breast
cancer survivors.
Methods
Newly diagnosed nonmetastatic breast cancer survivors (n = 344) and matched controls without
cancer (n = 347) 60 years of age and older without dementia or neurologic disease were recruited
between August 2010 and December 2015. Data collection occurred during presystemic treatment/
control enrollment and at 12 and 24 months through biospecimens; surveys; self-reported Func-
tional Assessment of Cancer Therapy-Cognitive Function; and neuropsychological tests that
measured attention, processing speed, and executive function (APE) and learning andmemory (LM).
Linear mixed-effects models tested two-way interactions of treatment group (control, chemo-
therapy with or without hormonal therapy, and hormonal therapy) and time and explored three-way
interactions of ApoE (e4+ v not) by group by time; covariates included baseline age, frailty, race, and
cognitive reserve.
Results
Survivors and controls were 60 to 98 years of age, were well educated, and had similar baseline
cognitive scores. Treatment was related to longitudinal cognition scores, with survivors who re-
ceived chemotherapy having increasingly worse APE scores (P = .05) and those initiating hormonal
therapy having lower LM scores at 12 months (P = .03) than other groups. These group-by-time
differences varied by ApoE genotype, where only e4+ survivors receiving hormone therapy had
short-term decreases in adjusted LM scores (three-way interaction P = .03). For APE, the three-way
interaction was not significant (P = .14), but scores were significantly lower for e4+ survivors
exposed to chemotherapy (20.40; 95% CI, 20.79 to 20.01) at 24 months than e4+ controls (0.01;
95% CI, 0.16 to 0.18; P , .05). Increasing age was associated with lower baseline scores on all
cognitive measures (P , .001); frailty was associated with baseline APE and self-reported decline
(P , .001).
Conclusion
Breast cancer systemic treatment and aging-related phenotypes and genotypes are associated with
longitudinal decreases in cognitive function scores in older survivors. These data could inform
treatment decision making and survivorship care planning.
J Clin Oncol 36:3211-3222. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Cognitive problems commonly have been re-
ported among breast cancer survivors before and
after systemic therapy.1-12 However, these declines
are not universal,8,13,14 can be subtle, can vary by
treatment regimen, and may only affect certain
subgroups.15 Older survivors have not been well
studied, but should be at risk for cancer-related
cognitive decline1,2,6,15,16 because aging is associated
with an increasing incidence of neurodegenerative
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Fig 1. (A) Sample for evaluation of cognition in older breast cancer survivors and (B) matched controls without cancer. Participants were excluded if they failed the
cognitive screen (at baseline). The percentagewho consented and refusedwas calculated among those alive and eligible to continue the study at each time point. Eligibility
for continuing in the study was the same as enrollment eligibility and included development of a neurologic disease (eg, stroke, Parkinson’s disease) and a diagnosis
of cancer. Survivors who were diagnosed with breast cancer recurrence were excluded from assessment for the 6 months before diagnosis of recurrence. Participants
may have refused an interview at one time point but then completed later interviews. Most participants completed two or three assessments (continued on next page)
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disease and shares many common biologic pathways with putative
mechanisms of cancer-related cognitive decline.15 Furthermore,
chemotherapy produces changes in biomarkers17 and brain struc-
ture that mimic aging.18-21 Chronologic age and aging phenotypes,
such as frailty22 and/or high comorbidity burden, may be markers
for risk of cognitive decline.3 Genotypes associated with neurode-
generative disease, including polymorphisms in the apolipoprotein E
(ApoE) gene, a risk factor for Alzheimer’s disease, also have been
reported to be associated with cancer-related cognitive decline.2,23,24
Identification of specific risk factors for cancer-related cog-
nitive decline in older populations has important implications for
oncology care1 because 75% of breast cancer survivors in the
United States are 60 years of age and older25 and because detection
of subtle cognitive problems can be challenging in practice.2,26,27
Among the few prospective studies that have examined risk of
cognitive decline in older survivors,3,26 few included a contem-
poraneous noncancer control group to assess the effect of aging28
or examine whether risk factors vary in their effects by treatment
regimen.2,26
Thinking and Living With Cancer (TLC) is a multisite pro-
spective study designed to fill this clinical gap. We used data from
older breast cancer survivors and matched controls without cancer
followed for 24 months to evaluate cognition after breast cancer
and its therapies relative to that seen with aging alone. We focused
on two cognitive domains related to aging and commonly affected
in cancer-related cognitive decline: attention, processing, and
executive function (APE) and learning and memory (LM).1,2 We
tested the hypothesis that older survivors exposed to chemotherapy
(with or without hormonal therapy) would have lower neuro-
psychological domain and self-reported cognitive scores over time
than survivors who received hormonal therapy only or controls.
We also examined whether age, frailty, or comorbidity was in-
dependently related to cognitive scores and explored whether ApoE
gene polymorphisms affected the differences in cognitive domain
scores among treatment groups over time. The results are intended
to inform clinical practice.
METHODS
This study was conducted at Georgetown University and affiliated practices
in the Washington, DC, area; Memorial Sloan Kettering Cancer Center;
Moffitt Cancer Center; City of Hope Comprehensive Cancer Center;
Hackensack University Medical Center; Indiana University (IU) School of
Medicine; and University of California, Los Angeles. IU and University of
California, Los Angeles, joined the study for laboratory support and IU for
participant recruitment in 2016, so data in this report are from the five
other sites. All institutional review boards approved the protocol.
Setting and Population
We included participants recruited between August 1, 2010, and
December 31, 2015; the study is ongoing. Eligible survivors were 60 years
of age or older, newly diagnosed with primary nonmetastatic breast cancer,
and English speaking. Those with stroke, head injury, major axis I
psychiatric disorders, and neurodegenerative disorders were ineligible.
Survivors with a history of other cancers were excluded if active treatment
was for less than 5 years or they had systemic therapy. Among eligible
survivors, 355 consented (36.5%; consent rate across sites, 17.2% to 72.7%;
median, 62.5%; Fig 1). Consenting survivors were similar in age to
nonparticipants.
There were 362 consenting controls without cancer, including 88
friends. When no friend was available, we recruited age-, race-, education-,
and site-frequency–matched controls. All controls met the same eligibility
criteria as survivors.
Participants were screened using the Mini-Mental State Examination
and the Wide Range Achievement Test 4 (WRAT4) Word Reading subtest;
those with scores less than 24 or less than third-grade–equivalent reading
level were ineligible (one control and one survivor, respectively). Controls
who scoredmore than 3 standard deviations (SDs) below the control mean
baseline neuropsychological scores for their age- and education groupwere
ineligible post hoc (n = 8). Data for survivors who experienced a re-
currence (n = 1) were excluded for the 6 months before recurrence. Nine
consenting survivors and six controls did not complete baseline assess-
ments. The final sample included 344 survivors and 347 controls. Among
participants remaining alive and eligible, 73.6% and 70.5% of survivors
and 89.5% and 77.2% of controls completed 12- and 24-month assess-
ments, respectively (Fig 1).
Data Collection
Assessments included neuropsychological testing, a structured sur-
vey, and biospecimens for ApoE genotyping. Staff members were certified
bi-annually on neuropsychological test administration. ApoE genotype was
batch tested using TaqMan assays (rs429358 assay identifier: C_3084793_20;
rs7412 assay identifier: C_904973_10; Life Technologies, Carlsbad, CA) on
a 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific, Waltham,
MA); analyses were blinded to group and used TaqMan Genotyper Software
version 1.3 (Thermo Fisher Scientific).
Measures
Outcomes. The primary cognitive outcome was the domain-specific
scores on neuropsychological tests of APE (six tests)2,6,23; verbal LM (five
tests) was the other outcome of interest. Visuospatial ability (two tests) was
a secondary domain. We used recommended tests with established re-
liability and validity in older populations29-31 and included instruments
with equivalent forms31 where possible to minimize practice effects.
Factor analysis confirmed that domain structure and reliability were
consistent for survivors and controls at all time points (Appendix Table A1,
online only). A language domain included in earlier reports3 was dropped
because it was not a separate factor and had limited variation. The
visuospatial domain was not reported because of poor reliability. Sec-
ondary outcomes included cognitive subdomain scores and self-reported
cognition on the basis of the Functional Assessment of Cancer Therapy-
Cognitive Function (FACT-Cog32,33; Cronbach’s a = 0.96); declines of 5%
to 7%, or 7 to 10 points, were considered clinically meaningful.34
Variables. The primary predictor was treatment group (chemo-
therapy [with or without hormonal therapy], hormonal therapy only, or
noncancer control). We explored whether ApoE genotype (e4+ v not)
affected treatment group differences in cognitive scores over time and
examined whether baseline age, frailty, comorbidity burden (two or fewer v
more than two illnesses), or diabetes were independently related to
cognition.3 Frailty was measured using the Searle’s deficits accumulation
index.35-41 Our 40-item adapted index excluded cognition but included
baseline comorbidity; prediagnosis/pre-enrollment physical, social, role,
and emotional function using the 12-Item Short-Form Health Survey
(64% completed three, 21% completed two, and 15% completed baseline only). No significant differences existed in age, frailty, apolipoprotein E e4
status, or self-reported cognition by number of completed assessments. Those completing baseline only tended to have slightly lower baseline attention, processing
speed, and executive function and learning and memory scores than those completing two or more assessments and to be a survivor versus a control, which potentially
underestimated declines in mean post-treatment 12- and 24-month scores. SD, standard deviation.
(Continued).
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Table 1. Baseline Characteristics of Older Breast Cancer Survivor Versus Controls Without Cancer
Characteristic
Participants, No. (%)
Controls
(n = 347)
Survivors
(n = 344) P a
Survivors Who Received
Chemotherapy 6 Hormonal Therapy
(n = 94)
Survivors Who Received Hormonal
Therapy Only (n = 237) P b
Sociodemographic
Age, years .49 , .01
Mean (SD) 67.8 (7.0) 68.1 (6.1) 66.1 (4.8) 68.8 (6.4)
Range 60-91 60-98 60-84 60-98
Race .97 .67
White, non-Hispanic 273 (78.9) 271 (78.8) 73 (77.7) 189 (79.7)
Nonwhitec 73 (21.1) 73 (21.2) 21 (22.3) 48 (20.3)
Marital status , .01 .44
Married 163 (47.8) 197 (59.9) 53 (57.0) 138 (61.6)
Widowed, divorced, single 178 (52.2) 132 (40.1) 40 (43.0) 86 (38.4)
Mean education, years (SD) 15.4 (2.3) 15.1 (2.2) .08 15.3 (2.3) 15.1 (2.1) .56
Mean WRAT4 score (SD) 111.8 (16.1) 110.9 (15.4) .49 110.9 (15.3) 111.2 (15.8) .87
Family history of dementia .21 .34
Yes 121 (37.9) 101 (33.1) 31 (36.9) 65 (31.1)
No 198 (62.1) 204 (66.9) 53 (63.1) 144 (68.9)
Standardized, unadjusted baseline
cognition scores
Neuropsychological testingd
Mean APE (SD) 20.05 (0.04) 20.11 (0.04) .30 20.12 (0.07) 20.10 (0.05) .98
Mean LM (SD) 20.03 (0.04) 20.05 (0.05) .86 20.05 (0.09) 0.00 (0.06) .63
Mean self-reporte (SD) 129.1 (16.1) 128.2 (18.5) .51 128.9 (17.6) 127.7 (18.9) .62
Lifestyle factors
Smoking status .97 .75
Current/former smoker 152 (45.1) 147 (45.2) 43 (46.7) 99 (44.8)
Never smoked 185 (54.9) 178 (54.8) 49 (53.3) 122 (55.2)
Current alcohol use .18 .24
Unknown/refused 39 (11.2) 52 (15.1) 14 (14.9) 36 (15.2)
Nondrinker 45 (13.0) 57 (16.6) 17 (18.1) 38 (16.0)
# 1 drink/d 197 (56.8) 173 (50.3) 52 (55.3) 113 (47.7)
. 1 drink/d 66 (19.0) 62 (18.0) 11 (11.7) 50 (21.1)
Mean age at menopause (SD) 49.5 (6.0) 48.8 (6.9) .15 50.0 (5.8) 48.4 (7.2) .06
Hormonal replacement therapy (any
type, excluding oral
contraceptives)
.21 .64
Never/unsure 177 (51.0) 172 (50.0) 50 (53.2) 48.4 (7.2)
, 1 year 19 (5.5) 23 (6.7) 6 (6.4) 115 (48.5)
1 to , 5 years 60 (17.3) 47 (13.7) 12 (12.8) 17 (7.2)
5 to , 10 years 38 (11.0) 30 (8.7) 5 (5.3) 32 (13.5)
$ 10 years 53 (15.3) 72 (20.9) 21 (22.3) 25 (10.5)
Current use of hormonal therapy , .01 .41
Yes 37 (21.8) 2 (1.2) 0 (0.0) 2 (1.6)
No 133 (78.2) 171 (98.8) 42 (100.0) 121 (98.4)
Clinical factors
Frailtyf .02 .69
Prefrail/frail 60 (18.1) 81 (25.6) 22 (25.0) 59 (27.2)
Robust 272 (81.9) 236 (74.4) 66 (75.0) 158 (72.8)
Comorbidities
Mean No. (SD) 2.4 (1.8) 2.6 (1.9) .17 2.4 (2.1) 2.7 (1.9) .24
# 2 (median) 196 (58.2) 168 (52.7) .16 57 (63.3) 104 (47.9) .01
. 2 141 (41.8) 151 (47.3) 33 (36.7) 113 (52.1)
ApoE genotypeg .12 .19
ApoE e42 252 (75.0) 250 (79.9) 73 (84.9) 168 (78.1)
ApoE e4+ 85 (25.0) 63 (20.1) 13 (15.1) 47 (21.9)
AJCC stage — , .01
0 — 41 (12.0) 1 (1.1) 32 (13.5)
I — 190 (55.4) 36 (38.7) 152 (64.1)
II — 94 (27.4) 41 (44.1) 50 (21.1)
III — 18 (5.2) 15 (16.1) 3 (1.3)
Surgery type — .08
BCS 6 RT — 189 (55.4) 46 (48.9) 139 (59.4)
Mastectomy — 152 (44.6) 48 (51.1) 95 (40.6)
(continued on following page)
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(Cronbach’s a = 0.85)42; prediagnosis/pre-enrollment activities of daily
living and instrumental activities of daily living43; and baseline Timed Up
and Go score.44 Scores were categorized using established cut points
(robust, 0 to less than 0.2; prefrail, 0.2 to less than 0.35; frail, 0.35 or
greater).40
Several covariates were examined as possible confounders of the
effects of group on cognition. Sociodemographic measures included race
(white v nonwhite), cognitive reserve (WRAT4 score), self-reported family
history of dementia (first-degree relative, yes v no), married versus not
married, and years of education. Lifestyle habits included self-reported
ever use of any type of hormonal replacement therapy (excluding oral
contraceptives), cigarette smoking (ever/current v never), and current
alcohol use. Baseline function was assessed using the FACT-General
(Cronbach’s a = 0.71).45,46
Scores of 16 or greater on the Center for Epidemiologic Studies
Depression Scale defined clinical depression.47 The State-Trait Anxiety
Inventory was used to measure state anxiety (Cronbach’s a = 0.86).48
Fatigue was assessed using the FACT-Fatigue scale (Cronbach’s a = 0.90).49
Clinical variables included surgery type, breast irradiation, biomarkers,
and stage.
Statistical Analysis
Raw neuropsychological test results (Appendix Table A2, online
only) were standardized to z scores using the baseline means and SDs of
age- and education group–matched controls without cancer.50 Stan-
dardized z scores were calculated for domains (Appendix Table A3,
online only). Univariable tests compared characteristics by group and
evaluated potential confounders. All participants with complete baseline
data were included in the analyses, and the characteristics of those with
two to three assessments (v one) were evaluated for relationships to key
variables.
Linear mixed-effects models tested the protocol-specified analyses:
the presence of group-by-time and group-by-time-by-ApoE interactions
for cognitive domain, subdomain, and self-reported scores (and 95%
CIs). These models included a participant-specific random effect. Age,
race, WRAT4 score, and site were included as fixed effects to adjust for
potential confounding effects. Given strong correlations, frailty,
comorbidity, or diabetes was included in the models one at a time. We
estimated that there was 80% power to detect a group-by-time effect size
equivalent to a Cohen’s d of 0.3 when 30% to 40% of 342 survivors
received chemotherapy.
Table 1. Baseline Characteristics of Older Breast Cancer Survivor Versus Controls Without Cancer (continued)
Characteristic
Participants, No. (%)
Controls
(n = 347)
Survivors
(n = 344) P a
Survivors Who Received
Chemotherapy 6 Hormonal Therapy
(n = 94)
Survivors Who Received Hormonal
Therapy Only (n = 237) P b
Mean time since surgery to baseline,
days (SD)h
— 49.9 (54.9) — 29.4 (46.7) 55.8 (52.4) , .01
ER status — , .01
Positive — 301 (87.5) 65 (69.1) 236 (99.6)
Negative — 43 (12.5) 29 (30.9) 1 (0.4)
HER2 status — , .01
Positive — 39 (13.4) 25 (26.9) 14 (7.3)
Negative — 251 (86.6) 68 (73.1) 179 (92.7)
Mean physical function score before
diagnosisi (SD)
52.0 (7.1) 52.0 (7.0) .91 51.4 (7.9) 52.0 (6.8) .56
Mean emotional function score
before diagnosisi (SD)
56.3 (5.0) 57.1 (4.7) .04 57.9 (3.8) 56.8 (5.1) .06
Depressionj ($ 16 on CES-D) 18 (5.4) 43 (13.9) , .01 20 (23.0) 23 (10.9) , .01
Mean anxiety scorek (SD) 26.7 (5.7) 29.5 (8.4) , .01 31.5 (11.0) 28.7 (7.1) , .01
Mean fatigue scorel (SD) 46.4 (5.8) 43.1 (8.5) , .01 43.4 (8.0) 42.7 (8.8) .56
Mean baseline physical function
scorem (SD)
21.9 (2.4) 19.9 (3.9) , .01 19.8 (3.8) 19.9 (3.9) .97
Mean baseline emotional function
scoren (SD)
14.5 (1.6) 13.1 (2.8) , .01 11.9 (3.2) 13.5 (2.5) , .01
NOTE. Some percentages may not add to 100 because of missing data; 13 survivors were missing systemic therapy data. P values are based on x2 or t tests.
Abbreviations: AJCC, American Joint Committee on Cancer; APE, attention, processing speed, and executive function; ApoE, apolipoprotein E; BCS, breast-conserving
surgery; CES-D, Center for Epidemiologic Studies Depression Scale; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LM, learning andmemory;
RT, radiotherapy; SD, standard deviation; WRAT4, Wide Range Achievement Test 4 Word Reading subtest.
aSurvivors versus controls.
bSurvivors chemotherapy versus hormonal therapy.
cNonwhite includes black, Hispanic, and Asian American/Pacific Islander; one participant without cancer was missing race data.
dNeuropsychological test scores by domain. Cognitive scores were standardized using the sample mean and SD of age- and education group–matched baseline
controls. Hence, a score of 0 indicates a score at the mean of the control group; scores, 0 indicate lower scores than the mean of the control group, and positive scores
indicate scores higher than the mean of the control group.
eOn the basis of the Functional Assessment of Cancer Therapy (FACT)-Cognitive Function. Scores range from 0 to 148, with higher scores indicating better cognition;
declines of 5% to 7%, or 7 to 10 points, on this 148-point scale are considered clinically meaningful.34
fOn the basis of scores for baseline frailty adapted from Searle’s deficits accumulation index.35,36 Excludes cognitive function.
gConsent forApoE biospecimenswas provided by 97.1% and 98.3% of survivors and controls in the final analytic sample, respectively; 21 consenting survivors and four
controls were unable to provide a specimen, had a specimen with insufficient DNA, or were lost, so percentages do not add to 100. Twenty-four percent provided blood,
and 76% gave saliva using an Oragene kit (DNA Genotek, Ottawa, Ontario, Canada). Samples were tested while blinded to group status. Among those with an «4 allele,
only seven survivors and seven controls were homozygous.
hTime since surgery was not calculated for participants who underwent neoadjuvant therapy (six with lumpectomy and two with mastectomy).
iOn the basis of the 12-Item Short-Form Health Survey for the period 2 months before cancer diagnosis; higher scores indicate better function.
jDepression defined by score above the cut point of 16 on the CES-D.
kOn the basis of the State-Trait Anxiety Inventory. Scores range from 20 to 80, with higher scores reflecting more anxiety.
lOn the basis of the FACT-Fatigue. Scores range from 0 to 52; higher scores reflect less fatigue.
mOn the basis of the FACT-General Physical Well-Being subscale. Scores range from 0 to 24; higher scores reflect better function.
nOn the basis of the FACT-General Emotional Well-Being subscale. Scores range from 0 to 16; higher scores reflect better function.
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In sensitivity analyses, we evaluated effects of group on specific tests
or subdomain scores and whether fatigue, anxiety, depression, or smoking
changed conclusions about interactions. Finally, we explored two- and
three-way interactions of age with group and time. Analyses were con-
ducted using SAS 9.4.b statistical software (SAS Institute, Cary, NC).
RESULTS
Participants ranged in age from 60 to 98 years and had an average of
15 years of education. There were no baseline differences in
sociodemographic factors, cognitive scores, or ApoE genotypes
between survivors and controls, except survivors were more often
married and had a higher proportion who were frail (Table 1).
Twenty-seven percent of survivors received chemotherapy (with or
without hormonal therapy); the majority of chemotherapy regi-
mens were anthracycline based, and most hormonal treatment was
initiated with aromatase inhibitors (Table 1).
APE Domain
Cognitive scores tended to improve over time, consistent with
expected practice effects. However, there was a significant group-
by-time interaction (P = .05) where survivors exposed to che-
motherapy did not show practice effects and actually had declines
in adjusted mean APE scores, whereas the other groups increased
over time (Fig 2). Baseline frailty was an independent predictor of
baseline APE scores (P , .001; Table 2). In models that included
comorbidity or diabetes instead of frailty, those withmore than two
comorbid conditions (v two or fewer; P , .01) had significantly
lower baseline mean APE scores independent of other effects
(Appendix Table A4, online only), and diabetes (v no diabetes) was
borderline significantly associated with lower scores (P = .09;
Appendix Table A5, online only).
The three-way group-by-time-by-ApoE interaction was not
statistically significant for APE scores (P = .14; Table 2; Fig 3A).
Despite this, an inspection of the means indicated that the small
number of survivors who were ApoE e4+ and exposed to che-
motherapy had lower adjusted APE mean scores at 24 months
(20.40; 95% CI, 20.79 to 20.01) than the ApoE e4+ controls
(0.01; 95% CI, 0.16 to 0.18; P , .05).
Depression, anxiety, fatigue, or smoking and other lifestyle
factors did not affect the mean scores for the various group-by-
time or group-by-time-by-ApoE combinations (data not shown).
Results for the APE subdomain and individual test scores followed
a similar pattern as the overall domain results (data not shown).
Older age was significantly associated with lower baseline cognitive
scores, but the effects of treatment over time did not vary by age
(data not shown).
LM Domain
A significant group-by-time interaction was found where
survivors taking hormonal therapy alone had less improvement in
cognitive scores at 12 months than other groups but improved by
24 months (P = .03 for two-way interaction; Fig 2). There was also
a statistically significant group-by-time-by-ApoE interaction
(P = .03), where differences in LM scores between treatment groups
over time were largely confined to those who were ApoE e4+ and
initiated hormonal therapy. This group had a small LM decline at
12 months but subsequent improvement at 24 months, whereas
other genotypes and groups showed early improvements (Table 2;
Fig 3B). Frailty, comorbidity, diabetes, and other covariates did not
change the conclusions with regard to interaction effects. LM
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Fig 2. Adjusted mean cognitive scores over time for older breast cancer survivors and controls without cancer. Adjusted mean cognitive domain scores on the basis of
least squares means from linear mixed-effects models show scores at baseline, 12 months, and 24 months for three treatment groups, including survivors who received
chemotherapy with or without hormonal therapy, survivors who received only hormonal therapy, and controls. The models included as fixed effects time; group;
apolipoprotein E genotype; all two- and three-way interactions for group, apolipoprotein E, and time; baseline age; frailty; standardized Wide Range Achievement Test 4
score; race; and recruitment site. Adjusted mean scores are shown by treatment group and time for the (A) attention, processing speed, and executive function (APE)
domain (P = .05 for group-by-time interaction) and (B) learning and memory (LM) domain (P = .03 for group-by-time interaction) for the genotypes combined. (C) Self-
reported cognition scores on the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), with higher scores indicating better cognitive function.
Declines of 5% to 7%, or 7 to 10 points, on this 148-point scale are considered clinically meaningful.34 Tables 2 and 3 include the 95%CIs for eachmean score at each time
point and for each outcome.
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subdomain and individual test scores followed a similar pattern as
the overall domain results, and there was no interaction of age with
longitudinal treatment effects (data not shown).
Self-Reported Cognition
Self-reported cognition was moderately but significantly
correlated with APE and LM (Pearson’s r = 0.40 to 0.41 at baseline,
12, and 24 months; all P , .001). Adjusted mean self-reported
cognitive scores for survivors exposed to chemotherapy decreased
nonsignificantly, whereas the other groups did not change over
time (Fig 2). Baseline frailty was independently related to baseline
self-reported cognitive scores. ApoE e4+ survivors who received
chemotherapy showed a clinically meaningful decrease in adjusted
mean self-reported score (from 133.1 [95% CI, 123.1 to 143.0] at
baseline to 126.0 [95% CI, 114.0 to 138.0] at 24 months, a 7-point
mean decrease), but the group-by-time-by-ApoE interaction was
not statistically significant (Table 3; Fig 3C).
DISCUSSION
The TLC is one of the largest prospective, controlled studies of
cognitive function among older breast cancer survivors. Our re-
sults for the first 2 years after diagnosis indicate that systemic
treatment and aging-related genotype and phenotypes are asso-
ciated with cognitive decline. Older survivors exposed to che-
motherapy had significantly lower longitudinal cognitive function
scores on the APE domain than other groups, and this effect was
largely confined to those with the ApoE e4 allele. This genotype also
was associated with having lower LM scores after hormonal
Table 2. AdjustedMean APE and LMDomain Cognitive Scores AmongOlder Breast Cancer Survivors and ControlsWithout Cancer by Time, Treatment, and Genotype
Domain
Sample Size
(N = 603)
Adjusted Mean Cognitive z Score (95% CI)*
Overall P†Baseline 12 Months 24 Months
APE
Group-by-time interaction .05
Chemotherapy 80 20.25 (20.44 to 20.06) 20.22 (20.42 to 20.02) 20.27 (20.50 to 20.04)
Hormonal therapy 201 20.25 (20.38 to 20.12) 20.15 (20.28 to 20.01) 20.01 (20.15 to 0.14)
Control 322 20.19 (20.31 to 20.07) 20.12 (20.24 to 0.00) 20.04 (20.16 to 0.09)
Group-by-time by ApoE interaction .14
Survivor
Chemotherapy 6 hormonal therapy, ApoE e4+ 12 20.29 (20.61 to 0.03) 20.33 (20.67 to 0.01) 20.40 (20.79 to 20.01)
Chemotherapy 6 hormonal therapy, ApoE e42 68 20.21 (20.37 to 20.05) 20.10 (20.27 to 0.07) 20.14 (20.33 to 0.04)
Hormonal therapy, ApoE e4+ 41 20.31 (20.49 to 20.12) 20.26 (20.46 to 20.07) 0.02 (20.20 to 0.24)
Hormonal therapy, ApoE e42 160 20.19 (20.32 to 20.06) 20.03 (20.16 to 0.10) 20.03 (20.17 to 0.11)
Control
ApoE e4+ 81 20.19 (20.34 to 20.04) 20.12 (20.27 to 0.04) 0.01 (20.16 to 0.18)
ApoE e42 241 20.19 (20.31 to 20.07) 20.12 (20.24 to 0.00) 20.08 (20.21 to 0.04)
Age , .01
WRAT4 score , .01
Race, nonwhite‡ (v white non-Hispanic) , .01
Frailty (frail/prefrail v robust) , .01
LM
Group-by-time interaction .03
Chemotherapy 80 20.20 (20.45 to 0.05) 0.00 (20.27 to 0.27) 0.01 (20.28 to 0.31)
Hormonal therapy 201 20.12 (20.29 to 0.05) 20.05 (20.22 to 0.13) 0.09 (20.09 to 0.28)
Control 322 20.20 (20.35 to 20.05) 0.03 (20.13 to 0.18) 20.05 (20.21 to 0.11)
Group-by-time-by-ApoE interaction .03
Survivor
Chemotherapy 6 hormonal therapy, ApoE e4+ 12 20.23 (20.65 to 0.19) 20.06 (20.52 to 0.39) 20.02 (20.53 to 0.49)
Chemotherapy 6 hormonal therapy, ApoE e42 68 20.17 (20.38 to 0.04) 0.06 (20.17 to 0.28) 0.04 (20.20 to 0.28)
Hormonal therapy, ApoE e4+ 41 20.14 (20.38 to 0.10) 20.18 (20.44 to 0.09) 0.08 (20.20 to 0.37)
Hormonal therapy, ApoE e42 160 20.10 (20.27 to 0.06) 0.08 (20.09 to 0.26) 0.11 (20.08 to 0.29)
Control
ApoE e4+ 81 20.30 (20.49 to 20.10) 0.01 (20.19 to 0.21) 20.13 (20.34 to 0.08)
ApoE e42 241 20.10 (20.26 to 0.05) 0.05 (20.11 to 0.21) 0.02 (20.14 to 0.19)
Age , .01
WRAT4 score , .01
Race, nonwhite‡ (v white non-Hispanic) , .01
Frailty (frail/prefrail v robust) .20
NOTE.Mean score from linearmixed-effectsmodels; separatemodel for each domain. Among the 603 included in themodels, 79, 119, and 405 contributed one, two, or
three data points, respectively. All mean scores are from amodel that includes the covariates shown plus time; group; ApoE genotype; all two- and three-way interactions
for group, ApoE, and time; and recruitment site. Twenty-five controls and 63 survivors are not included in the model because of missing data on covariates.
Abbreviations: APE, attention, processing speed, and executive function; ApoE, apolipoprotein E; LM, learning andmemory; WRAT4,Wide Range Achievement Test 4.
*All cognitive scores are standardized using the sample mean and standard deviation of matched age- and education group–specific controls at baseline. A z score of
0 indicates that the result is equal to the control mean. A negative z score indicates that the result is lower than the control mean, and a positive z score indicates that the
result is higher than the control mean. The 95%CI is based on the adjustedmean and SE. Scores are expected to improve over time (ie, go from negative to positive, from
a lower to higher positive score) as a result of expected practice effects. Decline is considered when there is not the expected practice effect.
†The P values are shown for the interactions of interest and selected covariates.
‡Nonwhite race includes black, Hispanic, and Asian American/Pacific Islander.
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Fig 3. Adjusted mean cognitive scores
over time for older breast cancer survivors
and controls without cancer by apolipopro-
tein E (ApoE) status. Adjusted mean cogni-
tive domain scores on the basis of least
squares means from linear mixed-effects
models show scores at baseline, 12months,
and 24 months for three treatment groups,
including survivors who received chemo-
therapy with or without hormonal therapy,
survivors who received only hormonal ther-
apy, and controls. The models included as
fixed effects time; group; ApoE genotype; all
two- and three-way interactions for group,
ApoE, and time; baseline age; frailty; stan-
dardized Wide Range Achievement Test 4
score; race; and recruitment site. (A) Results
for the attention, processing speed, and
executive function (APE) domain for group-
by-time-by-ApoE e4 positivity, where ad-
justed means are plotted for participants
who areApoE e4+ andApoE e42 (P = .14 for
three-way interaction). (B) Results for the
learning andmemory (LM) domain for group-
by-time-by-ApoE e4 positivity, where ad-
justed means are plotted for participants
who are ApoE e4+ and ApoE e42 (P = .03
for three-way interaction). (C) Results for self-
reported cognition on the Functional As-
sessment of Cancer Therapy-Cognitive
Function (FACT-Cog) scale for group-by-time-
by-ApoE e4 positivity,where adjustedmeans
are plotted for participantswho areApoE e4+
and ApoE e42 (P not significant for three-
way interaction). Declines of 5% to 7%, or 7
to 10 points, on this 148-point scale are
considered clinically meaningful.34 Tables 2
and 3 include the 95% CIs for each mean
score at each time point for each outcome.
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therapy initiation. Older age and frailty were independently related
to lower baseline cognitive scores.
Most2,5,6,8,9,26,51 but not all13,14,52 studies of breast cancer–
related cognitive decline have reported cognitive problems after
chemotherapy among predominately younger survivors. The
current findings confirm an adverse effect of chemotherapy on
APE scores in older survivors on the basis of not only failure to
show the expected practice effects74 but also declining scores. In
other studies, the ApoE e4 genotype was linked to post-
chemotherapy decline in similar domains and with reductions in
gray matter in younger breast cancer23,53 and testicular cancer
survivors.54-57 The current data suggest a similar selective deficit in
APE among ApoE e4 carriers exposed to chemotherapy, but the
overall interaction effect was not statistically significant.
In our cohort, the ApoE e4 genotype also was associated with
small, nonpersistent decreases in LM scores after hormonal
therapy initiation. Some reports have noted decrements in LM after
hormonal therapy,58 but others have shown inconsistent
results.10-12,59 Because even short-term cognitive deficits are
meaningful to survivors, confirmation of our results and extension
of follow-up will be important. Additional knowledge about
genotype-treatment interactions could suggest mechanistic path-
ways, be used in decisions to recommend extended hormonal
therapy duration,60 and could potentially affect the use of direct-
to-consumer ApoE testing.61
Chronologic age and aging phenotypes also were associated
with lower baseline APE and self-reported cognitive function
scores. Baseline cognitive scores have been shown to be a predictor
of cognitive trajectories in other older cancer cohorts.39 These
results, together with the growing body of evidence from other
studies,1,2,15,28,62 support the idea that chemotherapy (and possibly
hormonal therapy) can lead to cancer-related cognitive declines
through acceleration of aging processes. Aging processes, ApoE e4
genotype, and insulin resistance (seen with diabetes, a common
comorbidity and component of frailty) each has been related to
inflammation, which in turn is one of the putative risks for cancer-
related cognitive decline and Alzheimer’s disease.63,64 Aging and
the ApoE e4 genotype also reduce brain plasticity and repair,
another possible mechanism of cancer-related cognitive decline.65
Biomarker and imaging studies may provide additional insights
into the role of aging processes in cancer-related cognitive decline.
For instance, Sanoff et al17 reported that chemotherapy exposure in
younger breast cancer survivors was associated with increased
expression of p16INK4a, a marker of cellular senescence, at levels
equivalent to 10 to 15 years of chronologic aging. Neuroimaging
studies of younger survivors have shown postchemotherapy de-
creases in frontal gray matter volume, abnormalities in brain
network structure, and lower hippocampal volume consistent with
aging.18-21 We suggest that future research on mechanistic path-
ways focus on areas of overlap among aging processes, Alzheimer’s
disease, and risks for cancer-related cognitive decline.
Despite the strength of the evidence and rigor of our design,
several limitations should be considered in interpreting the
findings. First, the functional effect of the observed cognitive
declines is uncertain, and we do not know whether survivors will
develop dementia-related diagnoses. Prior research with older
survivors found that accelerated self-reported cognitive decline is
associated with lower physical and emotional function over 7 years
postdiagnosis.39 Second, the study population was well educated,
cognitively intact at baseline, and recruited primarily from aca-
demic centers and affiliated community hospitals, which poten-
tially underestimates cognitive declines in general populations.
Table 3. Adjusted Mean Self-Reported Cognitive Function Scores Among Older Breast Cancer Survivors and Matched Controls by Time, Treatment, and Genotype
Domain
Sample Size
(N = 603)
Adjusted Mean Score (95% CI)*
P†Baseline 12 Months 24 Months
Group-by-time interaction .50
Chemotherapy 80 131.3 (125.4 to 137.3) 126.5 (120.1 to 132.8) 126.5 (119.6 to 133.4)
Hormonal therapy 201 127.4 (123.5 to 131.4) 127.1 (122.9 to 131.2) 126.5 (122.0 to 130.9)
Control 322 128.6 (125.0 to 132.2) 128.7 (125.1 to 132.3) 128.1 (124.4 to 131.9)
Group-by-time-by-ApoE interaction .94
Survivor
Chemotherapy 6 hormonal therapy, ApoE e4+ 12 133.1 (123.1 to 143.0) 127.5 (116.7 to 138.3) 126.0 (114.0 to 138.0)
Chemotherapy 6 hormonal therapy, ApoE e42 68 129.6 (124.7 to 134.6) 125.4 (120.1 to 130.7) 126.9 (121.3 to 132.5)
Hormonal therapy, ApoE e4+ 41 124.8 (119.0 to 130.5) 125.3 (119.1 to 131.4) 124.5 (117.5 to 131.4)
Hormonal therapy, ApoE e42 160 130.0 (126.1 to 133.9) 128.8 (124.7 to 132.9) 128.5 (124.2 to 132.8)
Control
ApoE e4+ 81 126.9 (122.2 to 131.5) 127.1 (122.4 to 131.8) 125.9 (120.9 to 130.9)
ApoE e42 241 130.4 (126.7 to 134.1) 130.4 (126.7 to 134.1) 130.3 (126.5 to 134.2)
Age .50
WRAT4 score .05
Race, nonwhite‡ (v white non-Hispanic) .60
Frailty (frail/prefrail v robust) , .01
NOTE. Adjusted mean score and 95% CI from a linear mixed-effects model. Among the 603 included in the model, 79, 119, and 405 contributed one, two, or three data
points, respectively. All mean scores are from amodel that included the covariates shown plus time; group;ApoE; all two- and three-way interactions for group,ApoE, and
time; and recruitment site. Twenty-five controls and 63 survivors are not included in the model because of missing data on covariates.
Abbreviations: ApoE, apolipoprotein E; Wide Range Achievement Test 4.
*From the Functional Assessment of Cancer Therapy-Cognitive Function. The score is 0 to 148; higher scores reflect better cognitive function. Scores are expected to
improve over time (ie, go from negative to positive, from a lower to higher positive score) as a result of expected practice effects.74 Decline is considered when there is
not the expected practice effect.
†The P values are shown for the interactions of interest and selected covariates.
‡Nonwhite race includes black, Hispanic, and Asian American/Pacific Islander.
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Third, despite the large sample, statistical power was low to detect
a significant three-way interaction of group-by-time-by-genotype
effects because relatively few underwent chemotherapy, and rates
of ApoE e4+ were low. Furthermore, too few participants had two
copies of the e4 allele to test dose-response relationships. Other
genotypes, such as COMT and BDNF, also may be important in
cancer-related cognitive decline.24,66 Pooling of samples from other
studies of older survivors using similar eligibility and assessments
could be used to confirm results and increase statistical power for
detecting significant gene-treatment effects on cognition over time.
Fourth, although we used recommended tests,29 drawing con-
clusions about whether specific subdomains were affected differ-
entially by treatment was difficult because many tests capture
multiple cognitive constructs, and some tests did not have alter-
native forms and might show greater improvement with practice
than tests with alternative forms. Fifth, there was limited treatment
variability, so the evaluation of specific agents was not possible.9
Hormonal therapy effects were based on treatment initiation and
assumed adherence for the first 24 months. Early discontinuation
as a result of cognitive problems could underestimate the effects of
this modality on outcomes. Finally, too few survivors had human
epidermal growth factor receptor 2–positive or hormone receptor–
negative tumors to assess the respective effects of trastuzumab
or chemotherapy alone. Future clinical studies and preclinical
experiments67,68 will be necessary to examine the separate and
combined effects and mechanisms of specific agents.
In summary, older breast cancer survivors with aging-related
phenotypes and genotypes may be at risk for cognitive decline,
especially after chemotherapy. These results could be useful in
several ways to clinicians who care for older adults. First, in-
formation about risks for cognitive decline could help clinicians to
discuss treatment options when chemotherapy is discretionary
because many older cancer survivors are concerned about cognitive
problems related to their cancer and its treatment.69-72 The low
percentage of older survivors with cognitive decline also could
provide some reassurance if chemotherapy is clinically indicated.
Second, knowledge of the cognitive effects of systemic therapy
could prompt plans for monitoring during survivorship care to
facilitate adherence to long-term cancer and other medical ther-
apies.73 Cognitive function monitoring also could be useful to flag
survivors at risk for impaired daily functioning as a consequence of
cognitive decline.39,51 Finally, geriatric assessments that measure
cognitive function before treatment and during the survivorship
phase of cancer care could provide data for risk prediction tools
and assist clinicians in identifying older adults for preventive or
other interventions to maximize function and healthy lifespans.
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Appendix
Table A1. Neuropsychological Tests and Domains Used to Assess Cognition in Older Breast Cancer Survivors and Matched Controls Without Cancer
Domain and Test
Cronbach’s a Factor Loading
First AuthorAll Survivor Control All Survivor Control
APE
Baseline 0.72 0.74 0.70
NAB Digits Forward 0.60 0.65 0.56 Stern31
NAB Digits Backward 0.57 0.60 0.58 Stern31
Trail Making A 0.66 0.61 0.68 Reitan*
Trail Making B 0.69 0.64 0.73 Reitan*
COWAT 0.55 0.60 0.48 Benton†
Digit Symbol Test 0.66 0.66 0.63 Wechsler‡
12 months 0.71 0.75 0.66
NAB Digits Forward 0.50 0.60 0.40
NAB Digits Backward 0.46 0.46 0.47
Trail Making A 0.72 0.75 0.68
Trail Making B 0.67 0.69 0.64
COWAT 0.62 0.66 0.59
Digit Symbol Test 0.68 0.66 0.71
24 months 0.74 0.77 0.71
NAB Digits Forward 0.61 0.67 0.53
NAB Digits Backward 0.60 0.64 0.54
Trail Making A 0.63 0.64 0.62
Trail Making B 0.68 0.69 0.66
COWAT 0.61 0.61 0.58
Digit Symbol Test 0.69 0.70 0.71
LM
Baseline 0.86 0.86 0.86
Logical Memory I 0.81 0.81 0.78 Abikoff§
Logical Memory II 0.83 0.85 0.78 Abikoff§
NAB List A Immediate Recall 0.73 0.72 0.76 Stern31
NAB List A Short Delay Recall 0.74 0.72 0.78 Stern31
NAB Long Delay 0.75 0.72 0.79 Stern31
12 months 0.88 0.87 0.88
Logical Memory I 0.78 0.80 0.76
Logical Memory II 0.82 0.82 0.83
NAB List A Immediate Recall 0.79 0.79 0.80
NAB List A Short Delay Recall 0.79 0.76 0.80
NAB Long Delay 0.82 0.80 0.84
24 months 0.89 0.87 0.91
Logical Memory I 0.84 0.81 0.85
Logical Memory II 0.87 0.83 0.88
NAB List A Immediate Recall 0.77 0.74 0.80
NAB List A Short Delay Recall 0.78 0.77 0.79
NAB Long Delay 0.76 0.77 0.76
Abbreviations: APE, attention, processing speed, and executive function; COWAT, Controlled Oral Word Association Test; LM, learning and memory; NAB,
Neuropsychological Assessment Battery.
*Reitan: Reitan Neuropsychology Laboratory, 1986.
†Benton: Annu Rev Psychol 45:1-23, 1994.
‡Wechsler: Psychological Corporation, 1997.
§Abikoff et al: J Clin Exp Neuropsychol 9:435-448, 1987.
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Table A3. Unadjusted Standardized Mean z Scores for Older Breast Cancer Survivors and Matched Controls Without Cancer by
Assessment Time and Treatment Group
Domain/Test
Control
(n = 347)
Survivor Chemotherapy 6 Hormonal
Therapy (n = 94) Survivor Hormonal Therapy Only (n = 237)
Baseline 12 Months 24 Months Baseline 12 Months 24 Months Baseline 12 Months 24 Months
APE 20.05 0.02 0.08 20.12 20.03 20.07 20.10 0.03 0.09
LM 20.03 0.16 0.10 20.05 0.18 0.17 0.00 0.14 0.21
NOTE. Survivor cognition scores are standardized using the baseline control mean and SD from age- and education-matched control groups. By definition, the control
mean z score is 0 with an SD of 1. Across controls, variation exists so that some controls have scores less than the control group mean (–) and others have scores higher
than the control group mean. Higher positive scores indicate better cognitive function. Over time, groups are expected to have scores that improve as a result of practice
effects.74 Hence, scores that show a failure to improve may indicate cognitive deficits.
Abbreviations: APE, attention, processing speed, and executive function; LM, learning and memory.
Table A2. Raw Baseline Neuropsychological Testing Scores of Pretreatment Cognitive Performance for Older Breast Cancer Survivors and Matched Controls Without
Cancer
Domain/Test
Study Group, Mean (SD)
Control
(n = 347)
Survivor
(n = 344)
Survivor Chemotherapy
(n = 94)
Survivor Hormonal Therapy
(n = 237)
APE
NAB Digits Forwarda 8.31 (2.36) 8.21 (2.31) 8.12 (2.13) 8.27 (2.39)
NAB Digits Backwarda 4.50 (2.18) 4.42 (2.14) 4.70 (2.09) 4.35 (2.18)
Trail Making Ab 36.90 (12.43) 37.41 (14.31) 35.25 (11.87) 38.22 (15.41)
Trail Making Bb 85.24 (43.32) 91.68 (48.36) 83.29 (48.46) 94.32 (48.74)
COWATc 43.22 (12.54) 40.78 (12.33) 41.15 (12.98) 40.76 (12.27)
Digit Symbol Testd 53.36 (10.46) 52.09 (11.51) 53.09 (11.12) 51.92 (11.64)
LM
Logical Memory Ie 13.17 (3.81) 12.79 (3.82) 12.98 (3.65) 12.79 (3.84)
Logical Memory IIf 11.86 (4.05) 11.61 (4.07) 12.16 (3.53) 11.48 (4.24)
NAB List A Immediate Recallg 23.06 (4.72) 22.55 (5.03) 22.99 (4.94) 22.43 (5.15)
NAB List A Short Delay Recallh 7.59 (2.48) 7.38 (2.66) 7.39 (2.49) 7.45 (2.72)
NAB List Long Delayi 7.65 (2.61) 7.51 (2.61) 7.54 (2.61) 7.58 (2.57)
NOTE. With the exception of Trail Making A and B, higher raw scores reflect better performance.
Abbreviations: APE, attention, processing speed, and executive function; COWAT, Controlled Oral Word Association Test; LM, learning and memory; NAB,
Neuropsychological Assessment Battery.
aNumber of sequences correctly recalled.
bTime in seconds.
cNumber of words given in allowed time.
dNumber of symbols produced in allowed time.
eNumber of pieces of a story recalled immediately.
fNumber of pieces of a story recalled after delay.
gSum of three trials of word recall.
hNumber of words recalled after short delay.
iNumber of words recalled after long delay.
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Table A4. Adjusted Mean Domain Scores Among Older Breast Cancer Survivors and Matched Controls Without Cancer by Time and Genotype: Comorbidity Effects
Domain Sample (N = 609)
Adjusted Mean Cognitive z Score (95% CI)*
P†Baseline 12 Months 24 Months
APE
Group-by-time interaction .05
Group-by-time-by-ApoE interaction .14
Survivor
Chemotherapy 6 hormonal therapy, ApoE e4+ 13 20.26 (20.58 to 0.06) 20.30 (20.64 to 0.03) 20.37 (20.76 to 0.02)
Chemotherapy 6 hormonal therapy, ApoE e42 69 20.20 (20.36 to 20.04) 20.09 (20.26 to 0.08) 20.13 (20.32 to 0.05)
Hormonal therapy, ApoE e4+ 41 20.27 (20.45 to 20.09) 20.23 (20.42 to 20.03) 0.06 (20.16 to 0.27)
Hormonal therapy, ApoE e42 160 20.16 (20.29 to 20.03) 0.00 (20.13 to 0.13) 0.00 (20.14 to 0.14)
Control
ApoE e4+ 83 20.15 (20.30 to 20.00) 20.08 (20.23 to 0.07) 0.05 (20.12 to 0.21)
ApoE e42 243 20.16 (20.28 to 20.04) 20.09 (20.21 to 0.03) 20.05 (20.18 to 0.07)
Age , .01
WRAT4 score , .01
Race, nonwhite‡ (v white non-Hispanic) , .01
Comorbidities (. 2 v # 2) , .01
LM
Group-by-time interaction .03
Group-by-time-by-ApoE interaction .03
Survivor
Chemotherapy 6 hormonal therapy, ApoE e4+ 13 20.20 (20.62 to 0.22) 20.03 (20.48 to 0.42) 0.01 (20.50 to 0.52)
Chemotherapy 6 hormonal therapy, ApoE e42 69 20.15 (20.36 to 0.05) 0.08 (20.15 to 0.30) 0.06 (20.18 to 0.30)
Hormonal therapy, ApoE e4+ 41 20.11 (20.35 to 0.13) 20.15 (20.41 to 0.11) 0.11 (20.17 to 0.39)
Hormonal therapy, ApoE e42 160 20.09 (20.25 to 0.08) 0.10 (20.08 to 0.27) 0.12 (20.06 to 0.30)
Control
ApoE e4+ 83 20.27 (20.46 to 20.08) 0.03 (20.17 to 0.23) 20.11 (20.32 to 0.11)
ApoE e42 243 20.08 (20.23 to 0.07) 0.07 (20.09 to 0.23) 0.05 (20.12 to 0.21)
Age , .01
WRAT4 score , .01
Race, nonwhite‡ (v white non-Hispanic) , .01
Comorbidities (. 2 v # 2) .79
NOTE. Mean score from a linear mixed-effects model. Among the 609 included in the model, 79, 121, and 409 contributed one, two, or three data points, respectively.
All mean scores are from amodel that included the covariates shown plus time; group; ApoE; all two- and three-way time, group, and ApoE interactions; and recruitment
site. Twenty-one controls and 61 survivors are not included in the model because of missing data on covariates.
Abbreviations: APE, attention, processing speed, and executive function; ApoE, apolipoprotein E; LM, learning andmemory; WRAT4,Wide Range Achievement Test 4.
*All cognitive scores are standardized tomatched age- and education group–specificmean control score at baseline. A z score of 0 indicates that the result is equal to the
control mean score. A negative z score indicates that the result is lower than the control mean, and a positive z score indicates that the result is higher than the control
mean. Scores are expected to improve over time (ie, go from negative to positive, from a lower to higher positive score) as a result of expected practice effects.74 Decline
is considered when there is not the expected practice effect.
†P values are shown for the interactions of interest and selected covariates.
‡Nonwhite race includes black, Hispanic, and Asian American/Pacific Islander.
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Table A5. Covariate-Adjusted Mean Domain Scores Among Older Breast Cancer Survivors and Matched Controls Without Cancer by Time and Genotype-Diabetes
Effects
Domain
Sample
(N = 607)
Adjusted Mean Cognitive z Score (95% CI)*
P†Baseline 12 Months 24 Months
APE
Group-by-time interaction .05
Group-by-time by ApoE interaction .15
Survivor
Chemotherapy 6 hormonal therapy, ApoE e4+ 13 20.30 (20.62 to 0.03) 20.33 (20.68 to 0.01) 20.40 (20.79 to 20.00)
Chemotherapy 6 hormonal therapy, ApoE e4- 69 20.22 (20.39 to 20.05) 20.11 (20.29 to 0.07) 20.15 (20.34 to 0.04)
Hormonal therapy, ApoE e4+ 41 20.30 (20.50 to 20.11) 20.26 (20.46 to 20.06) 0.02 (20.20 to 0.25)
Hormonal therapy, ApoE e42 159 20.20 (20.34 to 20.07) 20.05 (20.19 to 0.10) 20.05 (20.20 to 0.10)
Control
ApoE e4+ 83 20.19 (20.35 to 20.03) 20.12 (20.28 to 0.04) 0.01 (20.16 to 0.18)
ApoE e42 242 20.19 (20.32 to 20.06) 20.12 (20.25 to 0.01) 20.09 (20.22 to 0.05)
Age , .01
WRAT4 score , .01
Race, nonwhite‡ (v white non-Hispanic) , .01
Diabetes (yes v no) .09
LM
Group by time interaction .03
Group by time by ApoE interaction .03
Survivor
Chemotherapy 6 hormonal therapy, ApoE e4+ 13 20.14 (20.57 to 0.28) 0.02 (20.44 to 0.48) 0.07 (20.45 to 0.58)
Chemotherapy 6 hormonal therapy, ApoE e42 69 20.11 (20.33 to 0.10) 0.12 (20.12 to 0.35) 0.10 (20.14 to 0.35)
Hormonal therapy, ApoE e4+ 41 20.07 (20.32 to 0.18) 20.11 (20.38 to 0.16) 0.15 (20.14 to 0.45)
Hormonal therapy, ApoE e42 159 20.04 (20.22 to 0.13) 0.14 (20.04 to 0.33) 0.17 (20.02 to 0.36)
Control
ApoE e4+ 83 20.22 (20.43 to 20.02) 0.08 (20.13 to 0.29) 20.06 (20.28 to 0.17)
ApoE e42 242 20.03 (20.20 to 0.14) 0.12 (20.05 to 0.29) 0.09 (20.08 to 0.27)
Age , .01
WRAT4 score , .01
Race, nonwhite‡ (v white non-Hispanic) , .01
Diabetes (yes v no) .17
NOTE. Mean scores are from a linear mixed model. Among the 607 included in the model, 79, 121, and 407 contributed one, two, or three data points, respectively. All
mean scores are from amodel that included the covariates shown plus time, group;ApoE; all two- and three-way time, group, andApoE interactions; and recruitment site.
Twenty-two controls and 62 survivors are not included in the model because of missing data on covariates.
*All cognitive scores are standardized tomatched age- and education group–specificmean control score at baseline. A z score of 0 indicates that the result is equal to the
control mean score. A negative z score indicates that the result is lower than the control mean, and a positive z score indicates that the result is higher than the control
mean. Scores are expected to improve over time (ie, go from negative to positive, from a lower to higher positive score) as a result of expected practice effects.74 Decline
is considered when there is not the expected practice effect.
†P values are shown for the interactions of interest and selected covariates.
‡Nonwhite race includes black, Hispanic, and Asian American/Pacific Islander.
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